Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck, Austria.
Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackého tř. 1, 61242 Brno, Czech Republic.
Acta Biomater. 2019 Aug;94:425-434. doi: 10.1016/j.actbio.2019.06.026. Epub 2019 Jun 19.
Oral Immunization remains a challenge as antigens are rapidly metabolized in the gastrointestinal tract. In numerous previous studies, Self-emulsifying drug delivery systems (SEDDS) have demonstrated to be a promising tool for oral delivery of biologics. In this study, the potential of SEDDS as vehicle for oral vaccination has been evaluated. At this purpose, the model antigen Bovine serum albumin (BSA) has been incorporated in SEDDS after ion pairing. Squalane and monophosphoryl lipid A (MPLA) were chosen as adjuvants and dissolved in SEDDS containing BSA (SEDDS-BSA-squalane and SEDDS-BSA-MPLA). Formulations were administered orally to BALB/c mice. As control unformulated BSA was administrated orally (BSA-oral) and subcutaneously (BSA-sc). Systemic (anti BSA IgG titre) and mucosal (anti BSA IgA titre) immugenicity of BSA loaded in SEDDS and of unformulated BSA administered orally and subcutaneously was assessed and compared with each other. SEDDS-BSA-squalane and SEDDS-BSA-MPLA induced both higher anti BSA-IgG titre and anti BSA-IgA titre than orally administered unformulated BSA. BSA-sc induced the highest systemic immune response, however, the highest mucosal immune response was achieved via oral administration of SEDDS-BSA-squalane and SEDDS-BSA-MPLA. In general, SEDDS-BSA-MPLA showed the most promising systemic and mucosal immune response. According to these results, SEDDS seems to be a promising carrier for oral delivery of vaccines. STATEMENT OF SIGNIFICANCE: Oral vaccination is still a great challenge, as orally administered antigens are easily degraded in the gastrointestinal (GI) tract by peptidases and proteases. During the last years, self-emulsifying drug delivery systems (SEDDS) consisting of a mixture of oils and surfactants have been developed for the oral administration of hydrophilic macromolecular drugs. In this study, Bovine serum albumin (BSA) was chosen as model antigen and incorporated into self-emulsifying drug delivery systems (SEDDS) after hydrophobic ion pairing. Lipid A from Salmonella Minnesota R595 (MPLA) and squalane were chosen as adjuvants. SEDDS-BSA-MPLA and SEDDS-BSA-squalane were administered orally to mice. SEDDS-BSA-MPLA induced the strongest systemic (anti BSA-IgG titre) and mucosal (anti BSA-IgA titre) immune response. Based on these results, SEDDS are a promising alternative carrier for oral vaccine delivery.
口服免疫仍然是一个挑战,因为抗原在胃肠道中很快被代谢掉。在许多先前的研究中,自乳化药物传递系统(SEDDS)已被证明是生物制剂口服传递的有前途的工具。在这项研究中,评估了 SEDDS 作为口服疫苗载体的潜力。为此,模型抗原牛血清白蛋白(BSA)在离子对后被掺入 SEDDS 中。角鲨烷和单磷酰脂质 A(MPLA)被选为佐剂,并溶解在含有 BSA 的 SEDDS 中(SEDDS-BSA-角鲨烷和 SEDDS-BSA-MPLA)。制剂被口服给予 BALB/c 小鼠。作为对照,未配制的 BSA 被口服给予(BSA-口服)和皮下给予(BSA-皮下)。评估并比较了 SEDDS 中负载的 BSA 和口服和皮下给予的未配制 BSA 的全身(抗 BSA IgG 效价)和粘膜(抗 BSA IgA 效价)免疫原性。SEDDS-BSA-角鲨烷和 SEDDS-BSA-MPLA 诱导的抗 BSA-IgG 效价和抗 BSA-IgA 效价均高于口服给予的未配制 BSA。BSA-皮下注射诱导了最高的全身免疫反应,然而,通过 SEDDS-BSA-角鲨烷和 SEDDS-BSA-MPLA 的口服给予实现了最高的粘膜免疫反应。一般来说,SEDDS-BSA-MPLA 显示出最有前途的全身和粘膜免疫反应。根据这些结果,SEDDS 似乎是口服递送疫苗的有前途的载体。 意义声明:口服疫苗接种仍然是一个巨大的挑战,因为口服给予的抗原在胃肠道(GI)中很容易被肽酶和蛋白酶降解。在过去的几年中,自乳化药物传递系统(SEDDS)已被开发用于亲水大分子药物的口服给药,其由油和表面活性剂的混合物组成。在这项研究中,牛血清白蛋白(BSA)被选为模型抗原,并在疏水离子对后掺入自乳化药物传递系统(SEDDS)中。来自沙门氏菌明尼苏达州 R595(MPLA)的脂 A 和角鲨烷被选为佐剂。SEDDS-BSA-MPLA 和 SEDDS-BSA-角鲨烷被口服给予小鼠。SEDDS-BSA-MPLA 诱导了最强的全身(抗 BSA-IgG 效价)和粘膜(抗 BSA-IgA 效价)免疫反应。基于这些结果,SEDDS 是口服疫苗递送的有前途的替代载体。